Hesperos, Inc.
@HesperosInc
Hesperos is accelerating drug discovery with the world’s first, human based in vitro platform to accurately predict the safety and efficacy of therapeutics.
We are pleased to announce an exciting project with @Psilera, a biotech firm developing a novel psilocybin derivative for #FTD. We'll be supporting the preclinical development of PSIL-006, a promising new therapeutic candidate for this devastating disease. buff.ly/nYzJydp
New in Advanced Science: Our Human-on-a-Chip® platform was used to create what is believed to be the first digital twin from an organ-on-a-chip, predicting human efficacy and safety for antimalarial drugs. Read more: buff.ly/ZLqcigu #DigitalTwin #OrganOnAChip #NAMs
The FDA is moving away from mandatory animal testing. This @GENBio article highlights how the industry is responding with tools like Organ-on-Chip, organoids, and AI models. A great snapshot into what this means for the future of drug development. buff.ly/isMs7zx #FDA
Chief Scientist James Hickman will be on the panel at tomorrow's virtual Animal-Free Workshop Series for Early Career Researchers, hosted by @PCRM and @jhucaat, at 10 am EST. Register free at buff.ly/gTzodWV #NAMs #OrganOnAChip #HumanOnAChip #Biotech
The collaboration between Hesperos and Psilera reflects a shift toward technology like organ-on-a-chip being sought by @US_FDA. hubs.li/Q03rl-Wm0
Hesperos will be at @IAMBiotech's #BIO2025 next week! Connect with us at @BioFlorida's Florida Pavilion, booth #778, to learn more about our Human-On-A Chip technology. Learn more about BIO at buff.ly/2ku2NlB #biotech #MPS #NAMs #OrganOnAChip
Today we announced our partnership with @HesperosInc to advance preclinical development of our lead compound, PSIL-006, for the treatment of frontotemporal dementia (FTD). Read more: prnewswire.com/news-releases/… #FTD #Neuroplastogens #MindfulMedicine
Planning to attend the @MPSWorldSummit next week? Be sure to stop by Booth #301 to learn more about our Human-On-A-Chip technology. #MPS2025 #NAMs #Biotech #DrugDevelopment #OrganOnAChip
We are looking forward to next week's @MPSWorldSummit in Brussels! Members of our team will be presenting alongside other global leaders to discuss the latest advancements in organ-on-a-chip and other New Approach Methodologies (NAMs). Hope to see you there! #MPS2025 #NAMs
Join us for @NA3RsC's Multi Organ MPS workshop today, May 27, 10am EST. Hesperos will be 1 of 11 companies presenting multi organ models. Learn about the incredible work companies are doing in this space! Register to watch free at buff.ly/4eVwZiB #3Rs #MPS #NAMs
Hesperos Chief Scientist is presenting today at @StanfordMed’s Frontiers in Cardiovascular Science Symposium. He’ll share how our multi-organ #HumanOnAChip technology is accelerating therapeutic safety and efficacy evaluations. Watch free at: buff.ly/qtwtI2F
An insightful piece from @cenmag on the recent FDA announcement, which includes a quote from Hesperos cofounder and Chief Scientist James Hickman, PhD. We’re glad to contribute to the broader conversation on this important topic!
The FDA says that over the next 3–5 years it aims “to make animal studies the exception rather than the norm” for preclinical safety testing, starting with monoclonal antibodies and eventually encompassing all drugs. cen.acs.org/pharmaceutical…
Hesperos won the ACC.25 Pitch Challenge, hosted by @ACCinTouch! This shows the growing acceptance of our #HumanOnAChip especially with recent pronouncements from both the @US_FDA and @NIH supporting the adoption of #NAMs - including #OrganOnAChip models. buff.ly/QovBUbw
Congrats to our @jhucaat colleagues on their latest article exploring the current landscape and future direction of #MPS! Timely insights, especially in light of the recent @US_FDA roadmap to reduce reliance on animal models. Read more: buff.ly/ZrINaLk #NAMs #AltTox
Hesperos Co-founder and President Michael Shuler, PhD, is the keynote speaker at @Tech_Network's Innovations in Disease Modelling 2025! He'll discuss how #BodyOnAChip models like our #HumanOnAChip are advancing preclinical drug development. Register free buff.ly/v3EHyji
Exciting news! @US_FDA has announced a Roadmap to Reducing Animal Testing in Preclinical Safety Studies by leveraging more effective, human relevant methods - including #OrganOnAChip models like our #HumanOnAChip! buff.ly/BcxPIRQ #FDA #NAMs #AnimalTesting
Attending #AANAM this week? Catch Dr. Sandra Smieszek from @VandaPharma presenting on VCA-894A, a custom therapeutic for a #CMT2S patient. @Hesperos's #HumanOnAChip model showed it improved neuromuscular function & supported its FDA Orphan Drug Designation.buff.ly/GroAbr2
Hesperos scientist Kaveena Autar is presenting a poster next week at @AANmember's 2025Annual Meeting. Dr. Autar's poster will also be available for online viewing for attendees during her presentation time. Visit buff.ly/u7or1Oo to learn more. #AANAM #NAMs #HumanOnAChip
